Around 70% of children who survive a brain tumour develop at least one form of endocrine dysfunction, suggests a long-term study of patients attending a hospital in Portugal.
Collagenopathies could account for around one in 10 cases of familial short stature even when there are no obvious signs of dysplasia, say researchers.
A study of children with Noonan syndrome treated in clinical practice shows a good response to growth hormone treatment, with the majority achieving a height within population norms.
A longitudinal study of Finnish patients with juvenile acquired hypothyroidism has revealed that an abnormal growth pattern may be present for up to 5 years before diagnosis.
Children with idiopathic short stature and skeletal deformities should be tested for the NPR2 mutation, recommend Chinese researchers who believe that children with heterozygous mutations may benefit from recombinant human growth hormone therapy.
A single measurement of plasma levels of a fragment of type X collagen (Collagen X bioMarker) may give an instant picture of how fast a child is growing, say researchers.
The designation “Idiopathic short stature” was first used in the 1980s as a description for short children who had normal growth hormone secretion and otherwise unexplained short stature.
Rare copy number variants have been identified in a study of children who have growth hormone insensitivity or insulin-like growth factor-1 insensitivity, shedding light on the genetic basis of their conditions
Less than 10% of brain magnetic resonance imaging scans in children with isolated growth hormone deficiency reveal a pathological cause, say researchers.
Children who receive total body irradiation or craniospinal radiation for cancer may have a reduced response to growth hormone therapy if they later require it, say researchers.
